Use of clofarabine for acute childhood leukemia.

Biologics : Targets & Therapy
A PessionA Martoni

Abstract

A second-generation of purine nucleoside analogs, starting with clofarabine, has been developed in the course of the search for new therapeutic agents for acute childhood leukemia, especially for refractory or relapsed disease. Clofarabine is a hybrid of fludarabine and cladribine, and has shown to have antileukemic activity in acute lymphoblastic leukemia as well as in myeloid disorders. As the only new antileukemic chemotherapeutic agent to enter clinical use in the last 10 years, clofarabine was approved as an orphan drug with the primary indication of use in pediatric patients. Toxicity has been tolerable in a heavily pretreated patient population, and clofarabine has been demonstrated to be safe, both as a single agent and in combination therapies. Liver dysfunction has been the most frequently observed adverse event, but this is generally reversible. Numerous Phase I and II trials have recently been conducted, and are still ongoing in an effort to find the optimal role for clofarabine in various treatment strategies. Concomitant use of clofarabine, cytarabine, and etoposide was confirmed to be safe and effective in two independent trials. Based on the promising results when used as a salvage regimen, clofarabine is now be...Continue Reading

References

Apr 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·D A CarsonH B Cottam
Jan 24, 1992·Journal of Medicinal Chemistry·J A MontgomeryJ A Secrist
Jun 15, 1995·The New England Journal of Medicine·C H Pui
Jul 1, 1995·European Journal of Drug Metabolism and Pharmacokinetics·F AlbertioniJ Liliemark
Aug 31, 2002·Cancer Chemotherapy and Pharmacology·Takeshi TakahashiShiro Akinaga
Oct 12, 2002·Medical and Pediatric Oncology·Dawn Elizabeth McNeilAlvin Mauer
Mar 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hagop M KantarjianMichael Keating
Feb 22, 2005·Cancer Chemotherapy and Pharmacology·Todd CooperVarsha Gandhi
Aug 19, 2005·Leukemia·A PessionUNKNOWN AML Strategy & Study Committee of the Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP)
Sep 30, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrea PessionMaurizio Aricò
Jan 13, 2006·The New England Journal of Medicine·Ching-Hon Pui, William E Evans
Apr 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sima JehaPeter Steinherz
Feb 10, 2007·Expert Review of Anticancer Therapy·Sima Jeha, Hagop Kantarjian
Mar 30, 2007·British Journal of Haematology·Alex H BeesleyUrsula R Kees
Sep 14, 2007·Leukemia & Lymphoma·Hagop M KantarjianStefan Faderl
Aug 30, 2008·Cancer·Stefan FaderlHagop M Kantarjian
Jun 10, 2009·Expert Opinion on Drug Safety·Ulrike BacherAxel Rolf Zander
Jul 7, 2009·Biochemical Pharmacology·Anna ZhenchukFreidoun Albertioni
Aug 5, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sima JehaPeter Steinherz
Oct 15, 2009·Hematology/oncology Clinics of North America·Sima Jeha
Oct 21, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard H KoMignon L Loh
Dec 10, 2009·British Journal of Haematology·Christian M ZwaanUNKNOWN International BFM Study Group on Paediatric AML

❮ Previous
Next ❯

Citations

Dec 12, 2012·British Journal of Clinical Pharmacology·Johan G C van HasseltAlwin D R Huitema

❮ Previous
Next ❯

Methods Mentioned

BETA
deamination

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.